The US Food and Drug Administration's formal announcement that it would hold an advisory committee for Vascepa's expanded indication of cardiovascular risk reduction means that Amarin Corp. PLC is one step closer to a potentially significant new market. It also means that the company faces another big test in front of regulators with whom it has long had an adversarial relationship.
The fact that the advisory committee, scheduled for 14 November at the FDA's headquarters in Silver Spring, MD, is happening at all is not a great sign for the application
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?